Leerink downgraded BioNTech (BNTX) to Market Perform from Outperform with a $113 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer
- Goldman Sachs Picks 2 Stocks That Let Investors Buy the Dip or Ride the Momentum
- BioNTech Adds Chief People Officer to Management Board to Support Oncology Growth Strategy
- BioNTech appoints Jimenez as Chief People Officer
- BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX